A Phase 3 interventional study of Insulin glargine/Lixisenatide and IDegAsp in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 60 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2022, is one of 60 in phase 3, and was the 164th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 582 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 36th largest by enrollment of the 178 interventional ones that give a count, is one of 5 that started in 2022, is one of 80 in phase 3, and was the 179th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a parallel-group treatment, Phase 3, randomized, 2-arm study that assessed the efficacy and safety of iGlarLixi to IDegAsp in Chinese T2DM participants insufficiently controlled with oral antidiabetic drug(s).
Study details included:
27 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
at screening visit:
Exclusion Criteria:
Conditions/situations such as:
Laboratory findings tested at the screening visit:
The above information was not intended to contain all considerations relevant to a potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC) injection once daily on top of metformin +/- sodium-glucose co-transporter 2 inhibitor (SGLT-2i) for 24 weeks. Dose was individually adjusted.
Drug: Insulin glargine/Lixisenatide · Drug: Metformin · Drug: SGLT2 inhibitor
Participants self-administered IDegAsp (100 U/mL of insulin degludec + insulin aspart with a ratio of 70:30) SC injection once daily on top of metformin +/- SGLT-2i for 24 weeks. Dose was individually adjusted.
Drug: IDegAsp · Drug: Metformin · Drug: SGLT2 inhibitor
Drug pages: Insulin Glargine · Lixisenatide
solution, by subcutaneous injection
Drug pages: Insulin degludec · Insulin Aspart
solution, by subcutaneous injection
Tablet, orally
Tablet, orally
Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis
Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Change in HbA1c From Baseline to Week 24: Superiority Analysis
Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Change in Body Weight From Baseline to Week 24
Body weight was obtained with the participant wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Percentage of Participants Reaching HbA1c <7% at Week 24
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Percentages are rounded off to the tenth decimal place.
Time frame: Week 24
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. Percentages are rounded off to the tenth decimal place.
Time frame: Week 24
Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Hypoglycemia was characterized as per American Diabetes Association (ADA) 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 milligram/deciliter (mg/dL) (3.9 millimoles/liter \[mmol/L\]) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54 mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline up to Week 24
Change in Fasting Plasma Glucose From Baseline to Week 24
Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24
Participants were provided with a glucometer, corresponding supplies, a leaflet, and with diaries in order to perform self-measurement of plasma glucose and its recording and were trained on how to use the glucometer. The 7-point SMPG profile was measured at the following 7-points: pre-prandial (before starting a meal) and 2 hours postprandial each for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. The participants performed 7-point SMPG profile measurement over a single 24-hour period on 2 different days in the week. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Hypoglycemia was characterized as per ADA 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline up to Week 24
Percentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Participants who reached the specified target of HbA1c without any clinically significant symptoms of hypoglycemia as defined in ADA Levels 2 or 3 are reported. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline up to Week 24
Total Daily Insulin Dose at Week 24
Total daily insulin dose was defined as the sum of the insulin dose from study treatment and non-study treatment (e.g., rescue therapy). It was the average of the last 3 available insulin doses recorded in the electronic case report form in the week before visit.
Time frame: Week 24
Percentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold value was HbA1c \>8% at Week 12 or later on despite appropriate corrective actions. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline up to Week 24
Change in Fasting C-Peptide From Baseline to Week 24
Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
Time frame: Baseline, Week 24
Number of Participants With Any Hypoglycemia Event During On-Treatment Period
During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Number of participants who met ADA definition of hypoglycemia during the treatment period are reported. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. The on-treatment period (ie, treatment-emergent \[TE\] period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).
Time frame: From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)
Hypoglycemic Event Rate During the On-Treatment Period
During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Percentage of hypoglycemic events per participant-year during on-treatment period are reported. The on-treatment period (TE period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).
Time frame: From first dose of study drug up to 1 day after the last administration of study drug (maximum treatment exposure: 192 days)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events Of Special Interest (AESIs) and TEAEs Leading to Treatment Discontinuation
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any adverse event that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a suspected transmission of any infectious agent via an authorized medicinal product. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TE period was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days.
Time frame: From signature of the informed consent form up to the final visit regardless of seriousness or relationship to study drug (maximum treatment exposure: 192 days)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Vital Signs
Vital signs assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in sitting position with their arm outstretched in line with mid-sternum and supported and weight. Criteria for PCSA: SBP: \<=95 millimeters of mercury (mmHg) and decrease from baseline \>=20 mmHg, \>=160 mmHg and increase from baseline \>=20 mmHg; DBP :\<=45 mmHg and decrease from baseline \>=10 mmHg,\>=110 mmHg and increase from baseline \>=10 mmHg; HR: \<=50 beats/min and decrease from baseline \>=20 beats/min,\>=120 beats/min and increase from baseline \>=20 beats/min; Weight \>=5% decrease from baseline, \>=5% increase from baseline.
Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematology
Criteria for PCSA: For Hemoglobin (Hb), there are 3 criteria: (1)\<=115 grams (g)/L (Male\[M\]) or \<=95 g/L (Female\[F\]), (2)\>= 185 g/L (M) or \>=165 g/L (F), and (3) decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: \<100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]); \<2.0 Giga/L (Black \[B\]) or \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \>4.0 Giga/L; Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).
Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Clinical Chemistry
Criteria for PCSA: Lipase: \>=3 ULN; Amylase: \>=3 ULN; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Creatinine: \>=150 micromoles per liter (umol/L), \>=30% or \>=100% change from baseline; Glomerular filtration rate (GFR): \>=60-\<90 mL/minute(min)/1.73 square meter (m\^2) (mild decrease in GFR), \>=30-\<60 mL/min/1.73m\^2 (moderate decrease in GFR), \>=15-\<30 mL/min/1.73m\^2 (severe decrease in GFR),\<15 mL/min/1.73m\^2 (end stage renal disease); Creatinine clearance (CG): \>=60-\<90 mL/min (mild decrease in GFR), \>=30-\<60 mL/min (moderate decrease in GFR), \>=15-\<30 mL/min (severe decrease in GFR), \<15 mL/min (end stage renal disease); Urea nitrogen (BUN): \>=17 mmol/L and Uric acid: \<120 or \>408 umol/L; Alanine transaminase (ALT) and aspartate transaminase (AST): \>3/5/10/20 ULN. Alkaline phosphatase:\>1.5 ULN, total bilirubin (TBILI): \>1.5 or \>2 ULN, ALT and TBILI:\> ALT\>3ULN and TBILI \>2 ULN and Conjugated and total bilirubin: \>35% TBILI and TBILI \>1.5 ULN.
Time frame: From first dose of study drug up to 3 days after last administration of study drug (maximum treatment exposure: 192 days)
The study was conducted at 60 centers in China. A total of 733 participants were screened between 07-Jul-2022 and 17-Apr-2023, of which 151 were screen failures. Screen failures were mainly due to not meeting eligibility criteria.
| Milestone | iGlarLixi | IDegAsp |
|---|---|---|
| Started | 291 | 291 |
| Randomized and treated | 290 | 291 |
| Completed 24-week treatment period | 272 | 284 |
| Completed | 274 | 284 |
| Not completed | 17 | 7 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 13 | 4 |
| Withdrew: Non-compliance with study schedule | 2 | 1 |
| Withdrew: Other | 1 | 1 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| percentage of HbA1c | iGlarLixi | IDegAsp |
|---|---|---|
| Change in HbA1c From Baseline to Week 24: Non-Inferiority Analysis | -1.88 ± 0.05 | -1.68 ± 0.05 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| percentage of HbA1c | iGlarLixi | IDegAsp |
|---|---|---|
| Change in HbA1c From Baseline to Week 24: Superiority Analysis | -1.88 ± 0.05 | -1.68 ± 0.05 |
Body weight was obtained with the participant wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale was used throughout the study. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| kilogram | iGlarLixi | IDegAsp |
|---|---|---|
| Change in Body Weight From Baseline to Week 24 | -0.30 ± 0.29 | 1.19 ± 0.25 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7% at Week 24 | 72.5 | 59.8 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 | 40.5 | 21.3 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c or body weight value were considered as non-responders. During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Hypoglycemia was characterized as per American Diabetes Association (ADA) 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 milligram/deciliter (mg/dL) (3.9 millimoles/liter \[mmol/L\]) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54 mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7% With no Body Weight Gain at Week 24 and no Hypoglycemia During 24-Week Treatment Period | 26.5 | 13.4 |
Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| mmol/L | iGlarLixi | IDegAsp |
|---|---|---|
| Change in Fasting Plasma Glucose From Baseline to Week 24 | -3.18 ± 0.11 | -3.45 ± 0.11 |
Participants were provided with a glucometer, corresponding supplies, a leaflet, and with diaries in order to perform self-measurement of plasma glucose and its recording and were trained on how to use the glucometer. The 7-point SMPG profile was measured at the following 7-points: pre-prandial (before starting a meal) and 2 hours postprandial each for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. The participants performed 7-point SMPG profile measurement over a single 24-hour period on 2 different days in the week. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| mmol/L | iGlarLixi | IDegAsp |
|---|---|---|
| Change in Average 7-Point Self-Monitored Plasma Glucose (SMPG) Profile From Baseline to Week 24 | -3.36 ± 0.12 | -2.92 ± 0.11 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Hypoglycemia was characterized as per ADA 2021 recommendations. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7% at Week 24 With no Hypoglycemia During 24-Week Treatment Period | 43.6 | 35.7 |
Blood samples were collected at indicated timepoints for analysis of HbA1c. Participants without Week 24 HbA1c value were considered as non-responders. Participants who reached the specified target of HbA1c without any clinically significant symptoms of hypoglycemia as defined in ADA Levels 2 or 3 are reported. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7% at Week 24 With no Clinically Relevant Hypoglycemia During 24-Week Treatment Period | 66.7 | 56.0 |
Total daily insulin dose was defined as the sum of the insulin dose from study treatment and non-study treatment (e.g., rescue therapy). It was the average of the last 3 available insulin doses recorded in the electronic case report form in the week before visit.
| units | iGlarLixi | IDegAsp |
|---|---|---|
| Total Daily Insulin Dose at Week 24 | 27.68 ± 0.84 | 33.78 ± 0.83 |
Routine HbA1c value was used to determine the requirement of rescue medication. Threshold value was HbA1c \>8% at Week 12 or later on despite appropriate corrective actions. Percentages are rounded off to the tenth decimal place.
| percentage of participants | iGlarLixi | IDegAsp |
|---|---|---|
| Percentage of Participants Who Required Rescue Therapy During the 24-Week Treatment Period | 5.2 | 6.9 |
Blood samples were collected at fasting state (no food or drinks \[except water\] for at least 8 hours) at indicated timepoints. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| nanomoles/liter (nmol/L) | iGlarLixi | IDegAsp |
|---|---|---|
| Change in Fasting C-Peptide From Baseline to Week 24 | -0.23 ± 0.02 | -0.33 ± 0.02 |
During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Number of participants who met ADA definition of hypoglycemia during the treatment period are reported. * ADA Level 1 hypoglycemia: A measurable glucose concentration \<70 mg/dL (3.9 mmol/L) but \>=54 mg/dL (3.0 mmol/L). * ADA Level 2 hypoglycemia: Blood glucose concentration \<54mg/dL \[3.0 mmol/L\]; the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. * ADA Level 3 hypoglycemia: A severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. The on-treatment period (ie, treatment-emergent \[TE\] period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).
| Participants | iGlarLixi | IDegAsp |
|---|---|---|
| Number of Participants With Any Hypoglycemia Event During On-Treatment Period | 102 | 118 |
During the study, participants were instructed to document the presence of hypoglycemic episodes in their study diary. Percentage of hypoglycemic events per participant-year during on-treatment period are reported. The on-treatment period (TE period) was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days (1 day for hypoglycemia).
| event rate per participant-year | iGlarLixi | IDegAsp |
|---|---|---|
| Hypoglycemic Event Rate During the On-Treatment Period | 1.90 | 2.72 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any adverse event that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a suspected transmission of any infectious agent via an authorized medicinal product. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. TE period was defined as the period from the first injection study treatment to the last injection of study treatment + 3 days.
| Participants | iGlarLixi | IDegAsp |
|---|---|---|
| Any TEAE | 220 | 192 |
| Any TESAE | 15 | 12 |
| Any AESI | 6 | 2 |
| Any TEAE leading to treatment discontinuation | 7 | 1 |
Vital signs assessments included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in sitting position with their arm outstretched in line with mid-sternum and supported and weight. Criteria for PCSA: SBP: \<=95 millimeters of mercury (mmHg) and decrease from baseline \>=20 mmHg, \>=160 mmHg and increase from baseline \>=20 mmHg; DBP :\<=45 mmHg and decrease from baseline \>=10 mmHg,\>=110 mmHg and increase from baseline \>=10 mmHg; HR: \<=50 beats/min and decrease from baseline \>=20 beats/min,\>=120 beats/min and increase from baseline \>=20 beats/min; Weight \>=5% decrease from baseline, \>=5% increase from baseline.
| Participants | iGlarLixi | IDegAsp |
|---|---|---|
| SBP: <=95 mmHg and decrease from baseline >=20 mmHg | 1 | 1 |
| SBP: >=160 mmHg and increase from baseline >=20 mmHg | 4 | 7 |
| DBP :<=45 mmHg and decrease from baseline >=10 mmHg | 0 | 0 |
| DBP: >=110 mmHg and increase from baseline >=10 mmHg | 0 | 0 |
| HR: <=50 beats/min and decrease from baseline >=20 beats/min | 0 | 0 |
| HR: >=120 beats/min and increase from baseline >=20 beats/min | 0 | 0 |
| Weight: >=5% decrease from baseline | 41 | 19 |
| Weight: >=5% increase from baseline | 29 | 73 |
Criteria for PCSA: For Hemoglobin (Hb), there are 3 criteria: (1)\<=115 grams (g)/L (Male\[M\]) or \<=95 g/L (Female\[F\]), (2)\>= 185 g/L (M) or \>=165 g/L (F), and (3) decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: \<100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]); \<2.0 Giga/L (Black \[B\]) or \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \>4.0 Giga/L; Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).
| Participants | iGlarLixi | IDegAsp |
|---|---|---|
| Hb: <=115 g/L (M); <=95 g/L (F) | 4 | 1 |
| Hb: >=185 g/L (M); >=165 g/L (F) | 1 | 4 |
| Hb: Decrease from Baseline >=20 g/L | 25 | 19 |
| Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F) | 2 | 6 |
| Hematocrit: >=0.55 v/v (M) or >=0.5 v/v (F) | 37 | 30 |
| RBC: >=6 Tera/L | 5 | 6 |
| Platelets: <100 Giga/L | 3 | 7 |
| Platelets: >=700 Giga/L | 0 | 0 |
| WBC: <3.0 Giga/L (NB); < 2.0 Giga/L (B) | 2 | 3 |
| WBC: >=16.0 Giga/L | 1 | 0 |
| Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 5 | 7 |
| Lymphocytes: > 4.0 Giga/L | 4 | 6 |
| Monocytes: >0.7 Giga/L | 35 | 29 |
| Basophils: >0.1 Giga/L | 2 | 5 |
| Eosinophils: >0.5 Giga/L or >ULN | 2 | 2 |
Criteria for PCSA: Lipase: \>=3 ULN; Amylase: \>=3 ULN; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Creatinine: \>=150 micromoles per liter (umol/L), \>=30% or \>=100% change from baseline; Glomerular filtration rate (GFR): \>=60-\<90 mL/minute(min)/1.73 square meter (m\^2) (mild decrease in GFR), \>=30-\<60 mL/min/1.73m\^2 (moderate decrease in GFR), \>=15-\<30 mL/min/1.73m\^2 (severe decrease in GFR),\<15 mL/min/1.73m\^2 (end stage renal disease); Creatinine clearance (CG): \>=60-\<90 mL/min (mild decrease in GFR), \>=30-\<60 mL/min (moderate decrease in GFR), \>=15-\<30 mL/min (severe decrease in GFR), \<15 mL/min (end stage renal disease); Urea nitrogen (BUN): \>=17 mmol/L and Uric acid: \<120 or \>408 umol/L; Alanine transaminase (ALT) and aspartate transaminase (AST): \>3/5/10/20 ULN. Alkaline phosphatase:\>1.5 ULN, total bilirubin (TBILI): \>1.5 or \>2 ULN, ALT and TBILI:\> ALT\>3ULN and TBILI \>2 ULN and Conjugated and total bilirubin: \>35% TBILI and TBILI \>1.5 ULN.
| Participants | iGlarLixi | IDegAsp |
|---|---|---|
| Lipase: >=3 ULN | 6 | 9 |
| Amylase: >=3 ULN | 0 | 0 |
| Sodium: <=129 mmol/L | 0 | 0 |
| Sodium: >=160 mmol/L | 0 | 0 |
| Potassium: <3 mmol/L | 0 | 0 |
| Potassium: >=5.5 mmol/L | 1 | 3 |
| Creatinine: >=150 umol/L | 0 | 1 |
| Creatinine: >=30% change from baseline | 36 | 29 |
| Creatinine: >=100% change from baseline | 0 | 1 |
| GFR: Mild decrease in GFR | 80 | 79 |
| GFR: Moderate decrease in GFR | 11 | 11 |
| GFR: Severe decrease in GFR | 0 | 1 |
| GFR: End stage renal disease | 0 | 0 |
| CG: Mild decrease in GFR | 80 | 85 |
| CG: Moderate decrease in GFR | 12 | 16 |
| CG: Severe decrease in GFR | 0 | 0 |
| CG: End stage renal disease | 0 | 0 |
| BUN: >=17 mmol/L | 0 | 0 |
| Uric Acid: <120 umol/L | 0 | 0 |
| Uric Acid: >408 umol/L | 104 | 108 |
| ALT: >3 ULN | 4 | 2 |
| ALT: >5 ULN | 1 | 0 |
| ALT: >10 ULN | 1 | 0 |
| ALT: >20 ULN | 0 | 0 |
| AST: >3 ULN | 0 | 0 |
| AST: >5 ULN | 1 | 0 |
| AST: >10 ULN | 0 | 0 |
| AST: >20 ULN | 0 | 0 |
| Alkaline Phosphatase: >1.5 ULN | 2 | 5 |
| TBILI: >1.5 ULN | 3 | 1 |
| TBILI: >2 ULN | 1 | 0 |
| ALT>3ULN and TBILI >2 ULN | 0 | 0 |
| Conjugated and TBILI: >35% TBILI and TBILI >1.5 ULN | 2 | 0 |
Collected over From signature of the informed consent form up to the final visit regardless of seriousness or relationship to study drug (maximum treatment exposure: 192 days). All-cause mortality was collected throughout the study, up to 67 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iGlarLixi | 0/290 (0%) | 15/290 (5.2%) | 152/290 (52.4%) |
| IDegAsp | 0/291 (0%) | 12/291 (4.1%) | 101/291 (34.7%) |
| Event | iGlarLixi | IDegAsp |
|---|---|---|
| Cerebral InfarctionNervous system disorders | 2/290 | 1/291 |
| Bronchopulmonary AspergillosisInfections and infestations | 1/290 | 0/291 |
| PneumoniaInfections and infestations | 1/290 | 0/291 |
| Ischaemic Cerebral InfarctionNervous system disorders | 1/290 | 0/291 |
| Vertebrobasilar InsufficiencyNervous system disorders | 1/290 | 0/291 |
| CataractEye disorders | 1/290 | 0/291 |
| Sudden Hearing LossEar and labyrinth disorders | 1/290 | 0/291 |
| Coronary Artery DiseaseCardiac disorders | 1/290 | 0/291 |
| Myocardial IschaemiaCardiac disorders | 1/290 | 1/291 |
| Lung DisorderRespiratory, thoracic and mediastinal disorders | 1/290 | 0/291 |
| Event | iGlarLixi | IDegAsp |
|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 50/290 | 37/291 |
| Covid-19Infections and infestations | 39/290 | 31/291 |
| NauseaGastrointestinal disorders | 35/290 | 2/291 |
| HyperuricaemiaMetabolism and nutrition disorders | 26/290 | 24/291 |
| DizzinessNervous system disorders | 19/290 | 5/291 |
| Lipase IncreasedInvestigations | 19/290 | 16/291 |
| DiarrhoeaGastrointestinal disorders | 16/290 | 7/291 |
| VomitingGastrointestinal disorders | 15/290 | 0/291 |
Baseline characteristics were assessed for all randomized population.
| Age, Continuous(years) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Mean | 56.3 ± 10.2 | 57.5 ± 9.9 | 56.9 ± 10.0 |
| Sex: Female, Male(Participants) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Female | 141 | 136 | 277 |
| Male | 150 | 155 | 305 |
| Race/Ethnicity, Customized(Participants) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Asian | 291 | 291 | 582 |
| Glycated Hemoglobin (HbA1c)(percentage of HbA1c) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Mean | 8.58 ± 0.93 | 8.53 ± 0.90 | 8.55 ± 0.91 |
| Duration of type 2 diabetes(years) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Mean | 8.56 ± 5.68 | 9.06 ± 6.00 | 8.81 ± 5.84 |
| Body Mass Index (BMI)(kilograms/square meter (kg/m^2)) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Mean | 25.92 ± 3.47 | 25.42 ± 3.25 | 25.67 ± 3.37 |
| Randomization stratum of oral antidiabetic (OAD) (s) use at screening(Participants) | iGlarLixi | IDegAsp | Total |
|---|---|---|---|
| Metformin ± SGLT-2i | 151 | 151 | 302 |
| Metformin + other OAD | 140 | 140 | 280 |
| Prior use of SGLT-2i | 37 | 37 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2022 to primary completion in Oct 2023, 15 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Lixisenatide